查詢結果分析
來源資料
相關文獻
- The Use of Serum Free-to-Total Prostate Specific Antigen Ratio to Predict Pathological Stage and Gleason Grade of Prostate Cancer with PSA of 4-20 NG/ML
- Flutamide-Induced Liver Injury: A Case Report
- 攝護腺癌之化學藥物治療
- 攝護腺癌的放射線治療及其護理
- Free-to-total Serum Prostate Specific Antigen Ratio in Chinese Men
- 從末期攝護腺癌及乳癌來探討癌症病患荷爾蒙治療法之進展
- Detection of Prostatic Cancer Using Digital Rectal Examination, Prostate-Specific Antigen and Transrectal Ultrasonography
- Use of a Medical Decision Support System to Improve the Preoperative Diagnosis of Prostate Cancer with Pelvic Lymph Node Metastases
- Prostatic Carcinoma Presenting as Rectal Stenosis--A Case Report
- 攝護腺肥大患者之潛伏攝護腺癌
頁籤選單縮合
題 名 | The Use of Serum Free-to-Total Prostate Specific Antigen Ratio to Predict Pathological Stage and Gleason Grade of Prostate Cancer with PSA of 4-20 NG/ML=以自由型攝護腺特殊抗原的百分比預測攝護腺特殊抗原4-20ng/ml的攝護腺癌患者的病理期別及葛里森分數 |
---|---|
作 者 | 吳其翔; 張樹人; 林茂盛; | 書刊名 | 秀傳醫學雜誌 |
卷 期 | 6:1/2 民95.04 |
頁 次 | 頁1-8 |
分類號 | 416.275 |
關鍵詞 | 攝護腺癌; 自由型攝護腺特殊抗原; 病理期別; f/tPSA ratio; Prostate cancer; Pathological features; |
語 文 | 英文(English) |
中文摘要 | 攝護腺癌患者血清中的free PSA的百分比呈現較低的比值是已經確定的事實,然而,目前醫學尚無法確定free/total PSA ratio(f/tPSA)和攝護腺癌的病理期別的關係,在本院施行攝護腺根除性手術的186位病患中有66位PSA值介於4.0 – 20.0 ng/ml的患者,我們嘗試由這66位病患中找出f/tPSA和病理期別的相關性。66位病患中,將其分為兩組,第一組為PSA介於4.0 – 10.0 ng/ml有36位病人,第2組為10.0-20.0ng/ml有30位病人,f/tPSA以20%作為cutoff值。(1)病理期別:於第一組,f/tPSA≦20%時,T1c+T2有12位(44.4%),而T3有15位(55.6%),在f/tPSA>20%時則有8位(88.9%)屬於T2,有1位屬於T3(11.1%),有統計學上意義(P = 0.026)。於第二組,f/tPSA≦20%時,T2和T3各佔50%,在f/tPSA>20%時則有3位(75%)屬於T2,有1位屬於T3(25%),則無統計學上意義(P = 0.602)。(2)Gleason grade:於第一組,f/tPSA≦20%時有8位(28%)屬於favorablepathology,有19位(72%)屬於unfavorable pathology,在f/tPSA>20%時則有5位(56%)屬於favorable pathology,有4位(44%)屬於unfavorable pathology,無統計學上意義(P = 0.235)。第二組,也無統計學上意義(P = 1.0)。f/ tPSA ratio在PSA介於4.0 – 10.0ng/ml時,越低的ratio,其病理分期越晚期,Gleason grade在f/tPSA≦20%時,亦有增加的趨勢,但無統計學意義。對PSA>10 ng/ml之病人,f/tPSA ratio 則無法增加預測病理結果的能力。 |
英文摘要 | The value of the free/total prostate-specific antigen (f/tPSA) ratio in predicting the pathological stage and Gleason grade has remained controversial. In this study, we analyzed the relationship of the f/tPSA, prostate cancer pathological stage and Gleason grade in PSA level of 4.0-20.0 ng/ml. Total 66 patients were enrolled into this study. We divided the patients in 2 groups according to tPSA level. Group 1 was tPSA of 4.0-10.0 ng/ml, and Group 2 was tPSA of 10.0-20.0 ng/ml. The surgical specimens were examined with whole mount step section. We used the cutoff point of f/tPSA is 20%. Total and free PSA were determined using the immunoassays (Hybritech). Statistical analysis was used with Fisher exact test. As for pathological stage, in Group 1, when f/tPSA ratio > 0.2, there were 12 patients (44.45’r) with organ confined disease (pTlc+pT2) and 15 patients (55.6%) with pT3 or pT4. However, when f/tPSA ratio>0.2, whereas 8 patients (88.9%) with organ confined disease and only one patient (11.1%) with pT3. So, f/tPSA ratio as potential predictive of pathological stage when tPSA of 4.0-10.0 ng./ml (P=0.026). In Group 2, when f/IPSA ratio>0.2, there were 13 patients (50V) with organ confined disease and 13 patients (50%) with pT3 or pT4. likewise, when f/tPSA ratio > 0.2, whereas 3 patients (75%) with organ confined disease and one patient (25%) with pTS (P=0.602). As for Gleason grade, in Group 1, when f tPSA ratio > 0.2, there were 8 patients (28%) with favorable pathology, and 19 patients (72%) with unfavorable pathology. However, when f/tPSA ratio > 0.2, whereas 5 patients (56%) with favorable pathology, and 4 patients (44%) with unfavorable pathology, the differences were not statistically significant (P=0.235). In Group 2, there were also clearly no significant differences (P=1.0). Percent free PSA significantly predicted pathological stage of prostate cancer when serum PSA levels are 4.0-10.0 ng/ml (P 0.026). However, there was no significant relationship between f EPSA acid pathological features in serum PSA of 10.0-20.0 ng ml and Gleason grade in this study. |
本系統中英文摘要資訊取自各篇刊載內容。